These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 38540266)
1. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease? Takai K Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540266 [TBL] [Abstract][Full Text] [Related]
2. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103 [TBL] [Abstract][Full Text] [Related]
3. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213 [TBL] [Abstract][Full Text] [Related]
4. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819 [TBL] [Abstract][Full Text] [Related]
5. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434 [TBL] [Abstract][Full Text] [Related]
6. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370 [TBL] [Abstract][Full Text] [Related]
7. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500 [TBL] [Abstract][Full Text] [Related]
8. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome. Sumiyoshi R; Koga T; Kawakami A Biomedicines; 2024 May; 12(6):. PubMed ID: 38927348 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382 [TBL] [Abstract][Full Text] [Related]
14. International definition of iMCD-TAFRO: future perspectives. Nishimura Y; Nishimura MF; Sato Y J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. Nishikori A; Nishimura MF; Fajgenbaum DC; Nishimura Y; Maehama K; Haratake T; Tabata T; Kawano M; Nakamura N; Momose S; Sumiyoshi R; Koga T; Yamamoto H; van Rhee F; Kawakami A; Sato Y J Clin Pathol; 2024 Feb; ():. PubMed ID: 38378248 [TBL] [Abstract][Full Text] [Related]
16. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key. Zhou QY World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591 [TBL] [Abstract][Full Text] [Related]
17. Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980. Takeuchi K J Clin Exp Hematop; 2022; 62(2):79-84. PubMed ID: 35768240 [TBL] [Abstract][Full Text] [Related]
18. Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report. Shiina T; Yamamoto EK; Yamada H; Sendo S; Kanzawa M; Saegusa J Mod Rheumatol Case Rep; 2024 Aug; ():. PubMed ID: 39177383 [TBL] [Abstract][Full Text] [Related]
19. TAFRO Syndrome. Igawa T; Sato Y Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612 [TBL] [Abstract][Full Text] [Related]